The research in the “Molecular Targeted Therapies” group is focused on the development and evaluation of improved therapies that are directed to relevant molecular targets. Understanding the biological role of molecular targets – that are particularly relevant in certain diseases – is essential to design and develop effective targeted therapies. In cancer, for instance, the epidermal growth factor receptor (EGFR) is a recognized target for cancer imaging and therapy. Current therapies (e.g. photodynamic therapy, chemotherapy) can be ameliorated by improving their selectivity to cancer cells using vehicles that guide them to relevant targets on these cells. Targeting moieties or targeted nanoparticles are possibilities of such vehicles. Nanobodies are the targeting moiety employed in this research group and correspond to small antibody fragments derived from camelid heavy chain antibodies. This group employs relevant models to test these targeted therapies, and, when possible, experimental therapies are tested in the veterinary clinic, in collaboration with the University Clinic for Companion Animal Health. This exceptional step can provide critical insights into the feasibility of a new treatment in human patients, while it benefits animals in the veterinary clinic.